1CP
REGN icon

17 Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

17 Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
+537
New +$366K 0.15% 151

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

17 Capital Partners's REGN Position: Q2 2026 in Review

17 Capital Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 537 shares worth $335K. The stake represents 0.15% of the portfolio and ranks #151 among its holdings.

1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • 17 Capital Partners held 537 shares of Regeneron Pharmaceuticals worth $335K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new 17 Capital Partners position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.15% of 17 Capital Partners's portfolio in Q2 2026, its #151 holding.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.